The global Mammography Market size is expected to reach a value of USD 3.8 billion by 2028, according to a new report by Grand View Research, Inc. expanding at a CAGR of 10.0% from 2021 to 2028. The market growth can be attributed to the rising initiatives by various governments and NGOs to raise awareness about early diagnosis of microcalcifications in breast tissue. Some significant organizations such as the National Breast Cancer Foundation, CDC, and Breast Cancer Organization are promoting the early diagnosis of mammary gland calcification, which is one of the crucial factors expected to drive the demand over the forecast period.
Based on a report published by the National Cancer Institute in 2015, it was stated that the proportion of women aged 45 to 65 years had increased to 81.1% in breast cancer screening. Major mammography manufacturers are introducing new products and increasing the number of approved products, which is further expected to impel the demand in the coming years. In January 2016, FDA approved a new manual for digital mammography quality control by the American College of Radiology. The growing number of awareness campaigns to promote womens’ health services is also anticipated to propel growth. Some of the key industry players are Fujifilm; Hologic; Philips Healthcare; Siemens Healthineers; Toshiba Medical Systems Corporation; GE Healthcare; Metaltronica; PLANMED OY; Mindray Medical International Limited; and IMS srl. Related Press Release@ Mammography Market Report Mammography Market Report Highlights
0 Comments
The global Medical Disposables Market size is expected to reach USD 1086.6 billion by 2028, according to a new report by Grand View Research, Inc., expanding at a CAGR of 16.7% from 2021 to 2028. Rising incidence of Hospital Acquired Infections (HAIs), impact of COVID-19 outbreak, and increasing number of surgical procedures are the key factors driving the market for medical disposables.
Increasing number of surgeries globally is a key factor expected to drive the market over the forecast period. For instance, as per Mölnlycke Health Care AB, 70.00 million surgical procedures are performed every year in Europe. As such, medical disposable products such as hospital gowns, disposables eye gear, hand sanitizers, respiratory supplies, and sterilization supplies, which are being an essential requirement for surgical procedures, are expected to witness high demand over the forecast period. For instance, as per the report published by the Organization for Economic Co-operation and Development (OECD), around 390,352 surgeries were performed in Canada in 2017. Disposable products prevent the transmission of nosocomial infections to some extent owing to which surgeons consistently prefer to use disposable products over the reusable ones. Such factors are expected to boost market growth. Increasing incidence of HAIs due to lack of sanitation and precaution is also one of the leading factors contributing to the market growth. For instance, as per the CDC, about one in 25 hospital patients contracts at least one HAI every year. Non-woven disposables such as hospital gowns provide general protection against contamination and can help to lower the risk of contracting HAIs. Furthermore, they can prevent bacterial and other microbial infections from entering a patient’s body. Thus, surgeons recommend patients to wear disposable gowns before medical procedures. These factors are anticipated to propel the market growth over the forecast period. Related Press Release@ Medical Disposables Market Report Medical Disposables Market Report Highlights
![]() The global Preterm Birth And PROM Testing Market size is expected to reach USD 1.9 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 3.0% from 2021 to 2028. Key factors that can be attributed to market growth are rising number of preterm births in developed and emerging economies, improving access to advanced neonatal and maternal care facilities, and introduction of new POC diagnostic products over the forecast period. Preterm births are not specific to a particular geography and have been recognized as a worldwide concern. The risk of preterm births typically escalates with increasing average age of pregnant women. With growing awareness about preterm births and its consequence, the tendency of pregnant women to enroll for Premature Rupture of Membranes (PROM) testing during their pregnancy is anticipated to increase, for reassurance and monitoring of symptoms of preterm birth. Point-of-Care (POC) diagnostics have drastically altered the methodology of testing in various fields. With the help of advanced technology, devices are able to assess analytes in a given sample. Companies are focusing on R&D to increase specificity and sensitivity of devices, which lowers the error rate. Hence, emphasis is being given to reducing sample size required for other medical testing. Many low-income states like Bihar, Madhya Pradesh, Rajasthan, and Uttar Pradesh have low utilization of public healthcare services for female infants. Despite the availability of free healthcare services, only approximately 41% of admissions to the SNCUs are female infants. Hence, many states have banned gender revelation to the family before birth. India is the only large country where more female infants die than males. UNICEF plans to intervene by strengthening the health infrastructure, and reducing inequities of healthcare services, and improve healthcare outcomes. Related Press Release@ Preterm Birth And PROM Testing Market Report Preterm Birth And PROM Testing Market Report Highlights
![]() The global Branched Stent Grafts Market size is anticipated to reach USD 477.53 million by 2028, registering a CAGR of 7.9% from 2021 to 2028, according to a new report by Grand View Research, Inc. Continued robust growth in segments is an outcome of the growing diagnostic capturing of pre-ruptured aneurysms, expanding clinical coverage, and an overarching trend for endovascular aneurysm repair. In addition, the preference for endovascular treatment for aortic aneurysms further boosts the market growth. Around 28 million vascular surgeries have been postponed or canceled globally at the peak of the COVID-19 pandemic, which can seriously affect the market. Restrictions on the movement of goods and people gradually led to a decline in the uptake of nonelective surgeries, such as those resulting from trauma or acute conditions. In addition, extended factory closures by companies in several countries slowed down the manufacturing of products. With the rapid increase in the elderly population worldwide, the frequency of aortic aneurysms is likely to increase, which, in turn, is expected to contribute to market growth during the forecast period. In the U.S., aortic aneurysms were the leading cause of 9,923 deaths in 2018. Thoracic aortic aneurysm and AAA are types of aortic aneurysms; aneurysms can also occur in other parts of the body. The global market is fairly competitive. The most notable participants in the market are Medtronic, Terumo Corp., and Cardinal Health (Cordis). Key players are involved in new product launches, acquisitions, and partnerships to gain a competitive edge over each other. For instance, in March 2021, Medtronic collaborated with Spectrum Health to drive value in healthcare and improve outcomes for patients in West Michigan. In September 2020, Terumo Aortic launched the TREO Abdominal Aortic Stent-Graft System to expand the company’s aortic solutions offerings. Related Press Release@ Branched Stent Grafts Market Report Branched Stent Grafts Market Report Highlights
![]() The U.S. Cancer Biopsy Market size is expected to reach USD 15.98 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 11.0% from 2021 to 2028. The increasing usage of technologically advanced devices for the early detection of diseases is one of the key factors driving the market. A significant transaction from tumor to liquid biopsy is anticipated to increase the adoption of this technique in the market. Acknowledging this trend, several operating entities have undertaken various initiatives to expand their biopsy kits portfolio. For instance, in June 2021, Biocept, Inc. and Quest Diagnostics collaborated to offer NGS-based liquid biopsy testing for lung cancer diagnosis. Furthermore, supportive regulatory and reimbursement scenarios in the country have supplemented the market growth. The U.S. FDA is actively engaged in supporting the commercialization of cancer biopsy products and increasing the use of these assays in clinics. For instance, in March 2021, the U.S. FDA granted a breakthrough device designation to RaDaR-a liquid biopsy assay to detect minimal residual disease in early-stage cancer. Related Press Release@ U.S. Cancer Biopsy Market Report U.S. Cancer Biopsy Market Report Highlights
![]() The global miRNA Sequencing And Assay Market size is expected to reach USD 597.8 million by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 13.0% from 2021 to 2028. Prominent players, such as Illumina, PerkinElmer, Qiagen, and others offer advanced miRNA sequencing products for multiple clinical applications. Moreover, these companies have collaborated with research institutes to expand the application of miRNA sequencing and assay in research studies. The market holds a significant growth potential owing to the increasing application of miRNA sequencing and assay in the healthcare industry. For instance, several research studies demonstrate that miRNAs can be used as efficient biomarkers in the diagnosis and prognosis of cancer (breast, ovarian, cervical, and others), cardiovascular diseases, sepsis, and nervous system disorders. Therefore, miRNA sequence analysis is increasingly employed to analyze gene regulation in clinical disorders. As plasma from COVID-19 recovered patients is rich in antiviral miRNAs and antibodies, it has been employed to treat SARS-CoV-2 infected patients. This has led to an increase in research studies that focus on the sequence analysis of miRNAs (microRNA) from the patient as well as the virus. Related Press Release@ miRNA Sequencing And Assay Market Report miRNA Sequencing And Assay Market Report Highlights
![]() The global Membrane Oxygenators Market size is expected to reach USD 141.5 million by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 1.5% from 2021 to 2028. Key factors expected to boost the market include the growing prevalence of respiratory failures and cardiopulmonary diseases. Furthermore, there has been a rise in the number of patients suffering from COVID-19 and chronic obstructive pulmonary disease, which can require membrane oxygenators for treatment, enhancing their adoption. Technological advancements in medical devices are expected to further propel their demand in hospitals. Leading market participants operating in this industry are focusing on developing technologically advanced membrane oxygenators. For instance, in January 2019, Terumo Medical Corporation launched the smallest, lowest prime volume, full-size adult oxygenator-Capiox NX19-with Ultraprime technology. Significant features of this device are it minimizes inflammatory response and provides higher efficiency microemboli removal. Portable adaptors and compact membrane oxygenators in ECMO circuits have also been developed, which help in the transportation of critically ill patients. The recent developments in medical devices are estimated to drive market growth. Cardiovascular diseases are among the leading causes of death across the globe. As per the WHO, in 2016, around 17.9 million CVD-related deaths were reported globally. A membrane oxygenator is used to treat patients with cardiac and respiratory diseases. ECMO machine removes carbon dioxide and delivers oxygen in patients when the lungs and heart fail to carry out the process of blood oxygenation. Hence, the rising occurrence of cardiac and respiratory disorders is anticipated to create robust growth opportunities. Related Press Release@ Membrane Oxygenators Market Report Membrane Oxygenators Market Report Highlights
![]() The global Alopecia Market size is expected to reach USD 14.2 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.1% from 2021 to 2028. The strong presence of pipeline products and increasing approval for laser-based therapy to treat hair loss conditions are major factors anticipated to drive growth. Moreover, rising awareness among patients about alopecia and its treatments, increasing government initiatives, supportive regulations & laws, and improvements in healthcare infrastructure are factors expected to propel market growth over the forecast period. Technological advancements in alopecia treatment are among the key drivers of this market. There are two FDA-approved therapeutics for alopecia-Rogaine and Propecia. There has been an increase in market penetration of generics after patent expiries of both drugs. However, the launch of several promising pipeline candidates over the forecast years such as Xeljanz (tofacitinib), Breezula (clascoterone), Jakafi (ruxolitinib), SM04554, and Lumigan (Bimatoprost) is expected to substantially drive the growth of the market in the near future. The introduction of low-level laser therapy that helps stimulate hair growth is expected to increase the treatment rate among patients facing hair loss. In addition, the launch of laser caps, helmets, combs, and bands is also anticipated to boost the market growth. For instance, Capillus Laser Cap, iGrow Laser Helmet, iRestore Hair Growth System, and Hairmax Laser devices are some of the technologically advanced products available in the market. Moreover, the increasing prevalence of diseases such as cancer, Polycystic Ovary Syndrome, and rheumatoid arthritis which are associated with hair loss is also expected to boost the treatment rate of hair loss in the near future. For instance, as per the U.S. Department of Health and Human Services, nearly 5 million women in the U.S. are affected by PCOS. Furthermore, according to the GBD database, the prevalence of PCOS in European countries, such as France, increased from 872,351 to 882,322 in 2018 & 2019, respectively, and in the U.K., the prevalence was found to be 1,134,082 to 1,142,498. Market players are increasingly forming partnerships and licensing agreements to enhance their product capabilities and promote the outreach of their products. For instance, the iGrow laser system has a partnership with China Central Pharmaceuticals in China. China Central Pharmaceuticals holds exclusive distribution rights over Aspira in the country. Moreover, Capillus, LLC has collaborated with Svenson, a hair loss treatment clinic to expand the distribution of laser therapy caps in Europe and Asia Pacific region. The partnership with local players and service providers is expected to increase the adoption of innovative therapy for hair loss treatment. Additionally, companies are actively participating in scientific conferences and conducting awareness campaigns for creating brand awareness. For instance, in February 2021, Hairmax welcomed Mary Brunetti as the brand ambassador to increase brand awareness about dealing with COVID-19-induced hair loss, as well as hereditary loss. Moreover, it plans to leverage the popularity of the brand ambassador to showcase its target market as to how its products can help regrow and revitalize their hair. However, reimbursement remains one of the major challenges in this market. Since most of the treatment modalities are considered as not medically essential and are categorized as cosmetic procedures, the treatment for hair loss is generally not covered under insurance plans. Out-of-pocket expenses for alopecia treatment usually include prescription drug copays, frequent doctor visits, and co-insurance for procedures. Moreover, increasing adoption of substitutes, such as traditional medicines-Ayurvedic, Chinese, and herbal medications may hamper the growth of the market. Based on results from the GlaxoSmithKline plc sponsored survey, around 22.7% of the patients took Chinese medications for treating male androgenetic alopecia in South Korea followed by Taiwan with 22.0% patients. Related Press Release@ Alopecia Market Report Alopecia Market Report Highlights
![]() The global Contrast Enhanced Ultrasound Market size is estimated to reach USD 2.71 billion by 2028, expanding at a CAGR of 4.0%, according to a new report by Grand View Research, Inc. Introduction of affordable dyes, increasing sonography procedural volume, and contrast imaging modes becoming an integral feature of ultrasound systems are the prominent factors driving the market. The increasing prevalence of cardiovascular diseases, liver lesions, renal lesions, gastrointestinal diseases, and vascular diseases globally is anticipated to boost the market growth, as these are major areas of clinical application of Contrast-enhanced Ultrasound (CEUS) systems. The presence of several potential benefits in CEUS such as being completely radiation-free, quick, cost-efficient, and patient-friendly, in comparison to the contrast-enhanced CT/MRI, is expected to propel the growth of the market. Increasing approvals of CEUS by regulatory bodies for new indications are expected to propel the growth of the market during the forecast period. For instance, the ultrasound dyes which were originally indicated for cardiac imaging have received an extension of indication for pediatric and liver imaging in several countries. Request a free sample copy or view report summary: Contrast Enhanced Ultrasound Market Report Contrast Enhanced Ultrasound Market Report Highlights
|
Archives
October 2023
|